This week: SeaEnergy awaits the winds of change, Hutchison China MedTech fortifies its position and Filtronic looks vulnerable.
Brainjuicer Group Plc (BJU 145p / £18.75m)
Brainjuicer, the provider of innovative market research techniques, last week gave a trading update. It said that revenue from the Group's strategically important 'Juicy' products made significant gains in 2009 and now accounts for over 60 per cent of the Group's revenue (2008: 46 per cent). These products are being sold to some of the world's largest buyers of market research. In 2009 the Company's clients included 11 of the world's top 20 buyers of market research, up from 9 in 2008, and revenue from these clients grew by over 70 per cent. Client satisfaction remains high with repeat business at around 80 per cent.
The revenue increase was driven by continued strong progress in the US, growing at around 60 per cent, and by encouraging contributions from the new offices in Switzerland and Germany. (The Company's UK business recovered after a slow start to the year). Overall the Group achieved approximately 26 per cent revenue growth (21 per cent on a constant currency basis). The operating profit is up by more than 25 per cent whilst having at the same time invested more than ever before in developing and validating products, in back- office operations and in the Company's software platform.
John Kearon, CEO of BrainJuicer, commented: "The Board is confident that in 2010 we can continue to grow our business through further product innovation and increasing our market share with major multinational customers." Brainjuicer’s business model, despite market research being a tough area over the past 12 months, would appear to be a no-brainer.
Dhais (DHAP.PL 29.5p / £16.8m)
This PLUS quoted and Cardiff based UK leader in the marketing and retailing of hearing and mobility products, last week announced that it had purchased back 2,545,454 Ordinary shares at an aggregate price of £700,000 from Steven Wilkinson.
In June 2009, the Company announced the acquisition of the Hearsavers business from Hearsavers Limited, a hearing aid company in administration. Steve Wilkinson a director of Hearsavers Limited was appointed a director of the Company’s subsidiary Hearing Health and Mobility Ltd and subscribed for 2,545,454 Ordinary Shares in the Company at a subscription price of £0.275 per share. The payment for these shares was by way of…
